<table border="0" cellpadding="0" cellspacing="0" width="523" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13. Established and Other Potentially Significant Drug Interactions 
			</caption>
<tfoot>
<tr>
<td colspan="3">↓ = Decreased (induces lamotrigine gluronidation).<br/>↑ = Increased (inhibits lamotrigine glucuronidation).<br/>? = Conflicting data. <br/>
</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">Concomitant Drug<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Effect on<br/>            Concentration of<br/>Lamotrigine or<br/>Concomitant Drug <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Clinical Comment<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">   Estrogen-containing oral<br/>               contraceptive preparations <br/>   containing 30 mcg<br/>   ethinylestradiol and<br/>   150 mcg levonorgestrel <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓ lamotrigine<br/> <br/> <br/> <br/> <br/>↓ levonorgestrel<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Decreased lamotrigine levels <br/>            approximately 50%.<br/> <br/> <br/> <br/>Decrease in levonorgestrel <br/>            component by 19%.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">   Carbamazepine (CBZ) and<br/>               CBZ epoxide <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓ lamotrigine<br/> <br/> <br/> <br/>? CBZ epoxide<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Addition of carbamazepine<br/>            decreases lamotrigine<br/>concentration approximately <br/>40%.<br/> <br/>May increase CBZ epoxide <br/>            levels<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">   Phenobarbital/Primidone <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Decreased lamotrigine<br/>            concentration approximately <br/>40%.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">   Phenytoin (PHT) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Decreased lamotrigine<br/>            concentration approximately <br/>40%.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">   Rifampin <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Decreased lamotrigine AUC <br/>approximately 40%.<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">   Valproate <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↑ lamotrigine<br/> <br/> <br/> <br/>? valproate<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increased lamotrigine<br/>            concentrations slightly more <br/>than 2-fold.<br/> <br/>Decreased valproate<br/>            concentrations an average of <br/>25% over a 3-week period<br/>then stabilized in healthy<br/>volunteers; no change in<br/>controlled clinical trials in<br/>epilepsy patients.<br/>
</td>
</tr>
</tbody>
</table>